Dengyong Zhang | Cancer Cell Biology | Best Researcher Award

Posted on by sciencefather

Prof. Dengyong Zhang | Cancer Cell Biology | Best Researcher Award

Prof. Dengyong Zhang , The First Affiliated Hospital of Bengbu Medical university , China

Zhang Deng Yong is a highly accomplished medical professional and researcher specializing in hepatocellular carcinoma and cholangiocarcinoma. Born in Liu’an, Anhui Province, China, in 1989, he currently works as an attending doctor at the First Affiliated Hospital of Bengbu Medical College. Dr. Zhang earned his Bachelor’s and Master’s degrees from Bengbu Medical College and is currently pursuing a Doctor’s degree at Anhui Medical University. He is also a visiting scholar at MD Anderson Cancer Center. With an extensive portfolio of research, Dr. Zhang is known for his significant contributions to the study of cancer biology, particularly in liver and biliary cancers. His commitment to medical research and patient care positions him as a key figure in the field of oncology.

Publication Profile:

Scopus

Strengths for the Award:

Dr. Zhang Deng Yong exhibits exceptional skills and commitment to the field of medical research, particularly in oncology. His advanced academic qualifications (Doctor’s degree from Anhui Medical University and a Master’s degree from Bengbu Medical College) provide a solid foundation for his innovative research. He has made significant contributions to understanding the molecular mechanisms underlying various cancers, especially hepatocellular carcinoma and cholangiocarcinoma, as evidenced by his numerous impactful publications. His collaborative work, demonstrated through his visiting scholar position at the MD Anderson Cancer Center, speaks to his ability to engage in high-caliber research environments.

Areas for Improvement:

While Dr. Zhang’s research portfolio is robust, expanding his involvement in interdisciplinary research or establishing collaborations beyond oncology could open new avenues in cancer treatment and prevention. Additionally, enhancing his focus on translational medicine could bridge the gap between laboratory research and clinical application.

Education:

Dr. Zhang Deng Yong’s academic journey began at Bengbu Medical College, where he earned his Bachelor’s degree in Medicine (2007-2012). He furthered his education with a Master’s degree in Surgery from the same institution (2012-2015). Currently, he is pursuing a Doctor’s degree at Anhui Medical University (2021-2024), specializing in oncology and cancer treatment. His dedication to academic excellence is reflected in his continued involvement in both teaching and advanced clinical research. In addition to his formal education, Dr. Zhang has participated in various international conferences and academic collaborations, further strengthening his expertise in medical research and surgery.

Experience:

Dr. Zhang has a solid background in clinical practice and research. Since 2016, he has served as an attending doctor at the First Affiliated Hospital of Bengbu Medical College, where he specializes in oncology and surgery. He also worked as a resident at Lu’an Traditional Chinese Medicine Hospital from 2015 to 2016. In 2022, Dr. Zhang had the opportunity to enhance his research experience as a visiting scholar at MD Anderson Cancer Center, a leading institution in cancer research. His clinical experience, combined with his academic training, allows him to offer patients the highest standard of care while contributing to groundbreaking cancer research. His expertise in hepatocellular carcinoma and cholangiocarcinoma has made him a sought-after expert in his field.

Awards and Honors:

Dr. Zhang Deng Yong’s commitment to research and medicine has earned him various recognitions and funding opportunities. He was awarded a Natural Science Fund of Anhui Province support from 2018 to 2020. Additionally, his work has been widely recognized in the academic community, where he has acted as a reviewer for multiple prestigious journals such as Oncology Reports, Molecular Medicine Reports, Oncology Letters, and Experimental and Therapeutic Medicine. These roles reflect his standing in the medical and scientific community. His involvement in clinical and research innovation has placed him at the forefront of oncology research, especially in the areas of hepatocellular carcinoma and cholangiocarcinoma.

Research Focus:

Dr. Zhang’s research primarily focuses on cancer biology, particularly hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). He is dedicated to understanding the molecular mechanisms behind cancer progression, immune responses, and therapeutic resistance. His work includes investigating the roles of various genetic and epigenetic factors in the development of liver and biliary cancers, as well as identifying potential biomarkers for early diagnosis and prognosis. Dr. Zhang’s research extends to exploring novel therapeutic approaches, including immunotherapy, targeted therapies, and the use of CRISPR technology. His publications also delve into the immune landscape and molecular pathways that influence cancer progression, with an emphasis on improving patient outcomes through precision medicine. His passion for cancer research and patient care continues to drive his work and innovations in the field.

Publications Top Notes:

  1. Immunosenescence and immunotherapy in elderly patients with hepatocellular carcinoma 🧬🦠

  2. USP1 promotes cholangiocarcinoma progression by deubiquitinating PARP1 to prevent its proteasomal degradation 🧬⚡

  3. CRISPR screening identifies BET and mTOR inhibitor synergy in cholangiocarcinoma through serine glycine one carbon 🔬🧬

  4. MiR-186-5p prevents hepatocellular carcinoma progression by targeting methyltransferase-like 3 that regulates m6A-mediated stabilization of follistatin-like 5 💡🧬

  5. The COL7A1/PI3K/AKT axis regulates the progression of cholangiocarcinoma 🔬🧬

  6. Integrative analysis of bulk and single-cell transcriptomic data reveals novel insights into lipid metabolism and prognostic factors in hepatocellular carcinoma 🧬💡

  7. HSDL2 knockdown promotes the progression of cholangiocarcinoma by inhibiting ferroptosis through the P53/SLC7A11 axis ⚡🔬

  8. Application of mesohepatectomy with caudate lobectomy for the treatment of type III–IV hilar cholangiocarcinoma: a single-center retrospective study 🏥📑

  9. Prognostic model for hepatocellular carcinoma based on anoikis-related genes: immune landscape analysis and prediction of drug sensitivity 🔬💉

  10. Bile metabolites as diagnostic biomarkers for perihilar cholangiocarcinoma 🧬💡

Conclusion:

Dr. Zhang Deng Yong’s expertise in cancer research, particularly his contributions to hepatocellular carcinoma and cholangiocarcinoma, places him as a strong contender for the Research for Best Researcher Award. His dedication to advancing medical knowledge, coupled with his impressive list of publications and international collaboration, makes him an invaluable asset to the scientific community. With continued growth in clinical application, Dr. Zhang is poised for further recognition and impactful contributions to medical research.

 

 

 

Chang Feng | Cancer Cell Biology | Best Researcher Award

Posted on by sciencefather

Dr. Chang Feng | Cancer Cell Biology | Best Researcher Award

Dr. Chang Feng , Shanghai University , China

Chang Feng is a distinguished researcher in the fields of tumor molecular diagnosis, biosensing, and intelligent DNA. Born in Shanghai, China, on January 1, 1988, Chang Feng pursued a rigorous academic journey, completing his Ph.D. at Nanjing University (2015-2019) after earning his M.D. from Shanghai University (2012-2015). He is currently a lecturer at Shanghai University since 2019. Feng has contributed significantly to scientific advancements in cancer diagnostics, molecular biosensors, and cutting-edge DNA research. His works often involve the development of innovative detection techniques and the creation of novel DNA-based diagnostic systems. Feng has a collaborative approach, working with multiple researchers to achieve groundbreaking results. His publications in prestigious journals highlight his expertise in developing biosensors, RNA origami, and catalytic DNAzymes for biomedical applications.

Publication Profile: 

Scopus

Strengths for the Award:

Chang Feng’s research is exceptional and well-suited for the Best Researcher Award. His expertise spans across tumor molecular diagnosis, biosensor development, and intelligent DNA systems. His contributions to cancer diagnostics, bioimaging, and biosensing technologies are groundbreaking. Feng has published several high-impact articles in leading journals, demonstrating significant advancements in DNAzymes, electrochemical biosensing, and RNA origami. His work in designing innovative DNA-based diagnostic platforms and cancer therapies reflects his ability to integrate chemistry, biology, and engineering, providing novel solutions for clinical applications. Feng’s interdisciplinary approach and leadership in the field have earned him numerous collaborations with researchers and institutions globally, further enhancing his credibility as a top-tier researcher.

Areas for Improvements:

While Feng has made remarkable contributions to scientific research, one area for improvement is expanding his focus to more clinical applications of his findings. Commercializing his biosensing technologies for real-world healthcare implementation would increase the practical impact of his work. Additionally, improving outreach through public science communication could help raise awareness of his advancements and engage a broader audience.

Education:

Chang Feng received his M.D. from Shanghai University in 2015, where he developed a strong foundation in molecular biology, diagnostics, and bioengineering. His doctoral journey continued at Nanjing University (2015-2019), where he obtained his Ph.D. focusing on tumor molecular diagnosis and biosensing technologies. During his time at Nanjing University, Feng’s research concentrated on the development of DNA-based biosensors and new methodologies for cancer detection. His education at these esteemed institutions provided him with the technical expertise necessary to pioneer groundbreaking research in the field of molecular diagnostics. Feng’s academic training involved rigorous coursework in molecular biology, chemical engineering, and bioinformatics, contributing significantly to his current work in bioimaging, biosensing, and the development of intelligent DNA systems.

Experience:

Chang Feng has a strong academic and research career, currently serving as a lecturer at Shanghai University since 2019. Prior to his current role, he earned his Ph.D. at Nanjing University (2015-2019) and M.D. from Shanghai University (2012-2015). Throughout his career, Feng has collaborated with leading researchers, contributing to the development of innovative biosensing technologies and cancer diagnostics. His work includes advancing DNA-based biosensors, DNAzyme probes, and other cutting-edge diagnostic tools. As a lecturer, Feng mentors graduate students and participates in academic teaching and research projects. He has been involved in several collaborative publications that have furthered the field of molecular biosensors, focusing on intelligent DNA-based systems and tumor detection methodologies. Feng’s research experience combines theoretical knowledge with practical applications, making him a recognized figure in the field of biosensor research and molecular diagnostics.

Research Focus:

Chang Feng’s primary research focus lies in tumor molecular diagnosis, biosensor development, and intelligent DNA systems. He is particularly interested in advancing technologies for cancer detection through the application of molecular biosensors, bioimaging, and intelligent DNA devices. His research explores the use of DNAzymes, catalytic DNA molecules, and RNA origami for targeted molecular detection, with a focus on enhancing the sensitivity and specificity of cancer diagnostics. Feng’s work also investigates the use of biosensors for the detection of small molecules, leveraging innovative electrochemical and fluorescence-based platforms. His interdisciplinary approach combines elements of chemistry, biology, and engineering to create advanced diagnostic systems with potential clinical applications. Feng is dedicated to improving the efficiency of diagnostic tools and is committed to developing more accurate and faster methods for early cancer detection and molecular analysis.

Publications Top Notes:

  1. Single-cell analysis of highly metastatic circulating tumor cells by combining a self-folding induced release reaction with a cell capture microchip 🧬🔬 (Anal. Chem., 2021)
  2. Hierarchical biomarkers detection via a universal polydopamine probe catalyzed by a hexagonal star-nanostructured DNAzyme 🔬🧪 (Sensor. Actuat. B-Chem., 2022)
  3. Construction of a ternary complex based DNA logic nanomachine for a highly accurate imaging analysis of cancer cells 🧬💡 (ACS Sens., 2020)
  4. Lantern-shaped flexible RNA origami for Smad4 mRNA delivery and growth suppression of colorectal cancer 🧬🦠 (Nat. Commun., 2023)
  5. Liquid-colloid-solid modular assembly for three-dimensional electrochemical biosensing of small molecules 💧⚡ (Biosens. Bioelectron., 2024)
  6. Dual-targets binding protection mediated rolling circle transcription with tandem fluorescent RNA aptamers for label-free detection of liver cancer biomarkers 🧬🦠 (Sensor. Actuat. B-Chem., 2024)
  7. Cell-Free Biosensing Genetic Circuit Coupled with Ribozyme Cleavage Reaction for Rapid and Sensitive Detection of Small Molecules 🧬⚡ (ACS Synth. Biol., 2023)
  8. A portable and partitioned DNA hydrogel chip for multitarget detection 💧🧬 (Lab Chip., 2023)

Conclusion:

Chang Feng’s research in tumor molecular diagnostics, biosensors, and intelligent DNA is truly cutting-edge. His scientific rigor, collaboration with top researchers, and groundbreaking discoveries in cancer detection and biosensing technologies make him a deserving candidate for the Best Researcher Award. By continuing to bridge the gap between laboratory research and clinical applications, Feng will likely have an even greater impact in advancing medical diagnostics and therapeutic strategies.